PMID- 34003549
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 1365-2893 (Electronic)
IS  - 1352-0504 (Linking)
VI  - 28
IP  - 8
DP  - 2021 Aug
TI  - Only partial improvement in health-related quality of life after treatment of 
      chronic hepatitis C virus infection with direct acting antivirals in a real-world 
      setting-results from the German Hepatitis C-Registry (DHC-R).
PG  - 1206-1218
LID - 10.1111/jvh.13546 [doi]
AB  - Improvement of health-related quality of life (HRQoL) is frequently reported as a 
      benefit when treating hepatitis C virus infection (HCV) with direct acting 
      antivirals (DAA). As most of the available data were obtained from clinical 
      trials, limited generalizability to the real-world population might exist. This 
      study aimed to investigate the impact of DAA therapy on changes in HRQoL in a 
      real-world setting. HRQoL of 1180 participants of the German Hepatitis C-Registry 
      was assessed by Short-Form 36 (SF-36) questionnaires. Scores at post-treatment 
      weeks 12-24 (FU12/24) were compared to baseline (BL). Changes of >/=2.5 in mental 
      and physical component summary scores (MCS and PCS) were defined as a minimal 
      clinical important difference (MCID). Potential predictors of HRQoL changes were 
      analysed. Overall, a statistically significant increase in HRQoL after DAA 
      therapy was observed, that was robust among various subgroups. However, roughly 
      half of all patients failed to achieve a clinically important improvement in MCS 
      and PCS. Low MCS (p < .001, OR = 0.925) and PCS (p < .001, OR = 0.899) BL levels 
      were identified as predictors for achieving a clinically important improvement. 
      In contrast, presence of fatigue (p = .023, OR = 1.518), increased GPT levels 
      (p = .005, OR = 0.626) and RBV containing therapy regimens (p = .001, OR = 1.692) 
      were associated with a clinically important decline in HRQoL after DAA therapy. 
      In conclusion, DAA treatment is associated with an overall increase of HRQoL in 
      HCV-infected patients. Nevertheless, roughly half of the patients fail to achieve 
      a clinically important improvement. Especially patients with a low HRQoL seem to 
      benefit most from the modern therapeutic options.
CI  - (c) 2021 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons 
      Ltd.
FAU - Ohlendorf, Valerie
AU  - Ohlendorf V
AUID- ORCID: 0000-0003-2358-0100
AD  - Hannover Medical School, Hannover, Germany.
FAU - Schafer, Arne
AU  - Schafer A
AD  - Diabetes-Klinik Bad Mergentheim, Bad Mergentheim, Germany.
FAU - Christensen, Stefan
AU  - Christensen S
AD  - CIM Munster, Munster, Germany.
AD  - Department of Gastroenterology and Hepatology, Munster University Hospital (UKM), 
      Munster, Germany.
FAU - Heyne, Renate
AU  - Heyne R
AD  - Leberzentrum am Checkpoint, Berlin, Germany.
FAU - Naumann, Uwe
AU  - Naumann U
AD  - UBN/Praxis, Berlin, Germany.
FAU - Link, Ralph
AU  - Link R
AD  - MVZ-Offenburg GmbH /St. Josefs-Klinik, Offenburg, Germany.
FAU - Herold, Christoph
AU  - Herold C
AD  - Internisten am Ring, Nurnberg, Germany.
FAU - Schiffelholz, Willibold
AU  - Schiffelholz W
AD  - Gastroenterologische Schwerpunktpraxis, Augsburg, Germany.
FAU - Gunther, Rainer
AU  - Gunther R
AD  - Department of Internal Medicine I, Universitatsklinikum Schleswig-Holstein (UKSH, 
      Kiel, Germany.
FAU - Cornberg, Markus
AU  - Cornberg M
AUID- ORCID: 0000-0002-9141-8001
AD  - Hannover Medical School, Hannover, Germany.
FAU - Serfert, Yvonne
AU  - Serfert Y
AUID- ORCID: 0000-0002-6263-0230
AD  - Leberstiftungs-GmbH Deutschland, Hannover, Germany.
FAU - Maasoumy, Benjamin
AU  - Maasoumy B
AD  - Hannover Medical School, Hannover, Germany.
FAU - Wedemeyer, Heiner
AU  - Wedemeyer H
AD  - Hannover Medical School, Hannover, Germany.
AD  - Department of Internal Medicine I, Universitatsklinikum Schleswig-Holstein (UKSH, 
      Kiel, Germany.
FAU - Kraus, Michael R
AU  - Kraus MR
AD  - Kreiskliniken Altotting-Burghausen, Burghausen, Germany.
LA  - eng
GR  - Janssen-Cilag GmbH (until 14/07/20)/
GR  - Roche Pharma AG (until14/07/17)/
GR  - Bristol-Myers Squibb (until 14/07/20)/
GR  - Gilead Sciences GmbH/
GR  - Merck Sharp &amp; Dohme GmbH/
GR  - AbbVie DeutschlandGmbH &amp; Co. KG/
GR  - Deutsches Zentrum fur Infektionsforschung/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210608
PL  - England
TA  - J Viral Hepat
JT  - Journal of viral hepatitis
JID - 9435672
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - Hepacivirus
MH  - *Hepatitis C/drug therapy
MH  - *Hepatitis C, Chronic/drug therapy
MH  - Humans
MH  - Quality of Life
MH  - Registries
MH  - Treatment Outcome
OTO - NOTNLM
OT  - antiviral agents
OT  - hepacivirus
OT  - hepatitis C
OT  - quality of life
OT  - surveys and questionnaires
EDAT- 2021/05/19 06:00
MHDA- 2021/10/05 06:00
CRDT- 2021/05/18 12:30
PHST- 2021/03/10 00:00 [revised]
PHST- 2020/12/04 00:00 [received]
PHST- 2021/04/17 00:00 [accepted]
PHST- 2021/05/19 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
PHST- 2021/05/18 12:30 [entrez]
AID - 10.1111/jvh.13546 [doi]
PST - ppublish
SO  - J Viral Hepat. 2021 Aug;28(8):1206-1218. doi: 10.1111/jvh.13546. Epub 2021 Jun 8.